Oncostellae

Pipeline

Pipeline

OST-122     (IBD, fibrosis, CRC)

Oral, non-systemic JAK3/TYK2-ARK5 inhibitor

DISCOVERY 100%
PRECLINICAL 100%
PHASE I 100%
PHASE II 20%

OST-499    (CRC, Immune Activation, solid tumors)

Oral, non-steroidal GR antagonist

DISCOVERY 100%
PRECLINICAL 100%
PHASE I 5%
PHASE II 0%

OST-Xxx  (GI inflammation)

Oral, non-systemic steroids

DISCOVERY 70%
PRECLINICAL 0%
PHASE I 0%
PHASE II 0%